Introduction: Heart failure (HF) leads to significant morbidity and mortality and imposes a large economic burden. Although there have been several advances in HF monitoring and management, HF-rehospitalization remains a significant problem. Remote monitoring of HF to detect early signs of decompensation has emerged in past years as an option to prevent or reduce the incidence of HF rehospitalization. The CardioMEMS HF system is a wireless pulmonary artery (PA) pressure monitoring system that detects changes in PA pressure and transmits data to the healthcare provider. Since changes in PA pressure happen early in the course of HF decompensation, the CardioMEMS system allows the provider to institute timely intensification of HF therapies to alter the course. In trial and registry data, the use of the CardioMEMS HF system has been associated with reduction in HF hospitalization, improvement in quality of life, symptoms, and physical activity.

Areas Covered: This review will focus on the available data supporting its utilization in patients with HF.

Expert Opinion: CardioMEMS is relatively safe and cost-effective, reduces heart failure hospitalization rates, and fits into intermediate to high-value medical care.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17434440.2020.1779588DOI Listing

Publication Analysis

Top Keywords

cardiomems system
16
heart failure
12
changes pressure
8
cardiomems
5
system daily
4
daily management
4
management heart
4
failure review
4
review current
4
data
4

Similar Publications

Article Synopsis
  • * The CardioMEMS device provided real-time data on her heart health, enabling healthcare providers to make timely adjustments to her treatment plan, which helped maintain her stability during pregnancy.
  • * The report emphasizes the advantages of using the CardioMEMS system in high-risk pregnancies, showcasing that the patient avoided hospital admissions and successfully delivered a healthy baby vaginally.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the CardioMEMS™ HF System in 103 French patients to assess its feasibility, safety, and clinical benefits post-implantation.
  • Over two years, no device-related complications were reported, and the system showed a 50% reduction in heart failure hospitalizations compared to the year before implantation.
  • Additionally, patients experienced lower pulmonary artery pressures and improvements in their functional class and overall quality of life.
View Article and Find Full Text PDF

Introduction And Objectives: Left ventricular global longitudinal strain (LVGLS) is an indicator of myocardial function in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Nevertheless, it is not clear whether LVGLS correlates with filling pressures and cardiac output (CO) in an ambulatory setting. We aimed to assess whether LVGLS is associated with invasive pulmonary artery pressures (PAP) and CO in outpatients using the invasive remote monitoring CardioMEMS™ system.

View Article and Find Full Text PDF

Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial.

Europace

July 2024

Department of Cardiology, St Antonius Ziekenhuis Nieuwegein/AUMC Amsterdam, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.

Article Synopsis
  • - Study aimed to determine factors influencing early mortality after left atrial appendage occlusion (LAAO) to improve patient selection and cost-effectiveness for stroke prevention.
  • - Analyzed data from 1,020 patients, finding a 2-year mortality rate of 16.4%, with 50% of deaths attributed to non-cardiovascular causes, and identified six key predictors of mortality including age and heart failure.
  • - Concluded that as the number of risk factors in patients increased, the mortality rate rose significantly, underscoring the need for careful patient selection for LAAO procedures.
View Article and Find Full Text PDF
Article Synopsis
  • The CardioMEMS HF System is an approved device for monitoring heart failure in adults, helping to cut down hospital visits and enhance quality of life for certain patients.
  • It works by being implanted in the body to measure pulmonary arterial pressure, with data sent wirelessly to healthcare providers for remote adjustments in treatment.
  • While it shows promise for patients with congenital heart disease, more extensive studies are needed to confirm its effectiveness in this group.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!